FDA Clearance Tracker · P260007
Autus Size-Adjustable Valve
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 1, 2026
Approved
Time to decision
234 days
Received Feb 9, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P260007
- Device name
- Autus Size-Adjustable Valve
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Feb 9, 2026
- Decided
- Oct 1, 2026
- Decision
- Approved
Device type
- Device type
- Heart-valve, polymeric (SJL)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for AUTUS Size-Adjustable Valve: The AUTUS valve is indicated for the management of pediatric patients weighing greater than or equal to 10 kg who require surgical pulmonary valve replacement for dysfunctional native or surgically-repaired right ventricular outflow tract (RVOT), as determined by echocardiography to meet the following criteria: (1) severe pulmonary stenosis (i.e., right ventricle (RV) to pulmonary artery (PA) peak instantaneous gradient greater than or equal to 60 mmHg); (2) greater than or equal to moderate pulmonary regurgitation; or (3) greater than or equal to moderate pulmonary stenosis (i.e., RV to PA peak instantaneous gradient greater than or equal to 40 mmHg) and greater than or equal to moderate pulmonary regurgitation.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SJL (Heart-valve, polymeric).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
K251326 · Decided Jun 11, 2026 · 408 days after receipt
Device type: Monitor, Breathing Frequency (BZQ) · Anesthesiology & Respiratory
K253186 · Decided Feb 24, 2026 · 151 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.